Koen Andries

发表

A comparative test of 15 compounds against all rhinoviruses as a basis for a more rational screening

Paul J. Lewi, Koen Andries, B. Dewindt, 1991 .

On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data

Eddy Arnold, Paul J. Lewi, Kalyan Das, 2003, J. Comput. Aided Mol. Des..

Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis

Koen Andries, Thomas Ioerger, J. Sacchettini, 2016, Antimicrobial Agents and Chemotherapy.

TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1

Koen Andries, Hilde Azijn, Theo Thielemans, 2004, Antimicrobial Agents and Chemotherapy.

Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.

Christophe Meyer, Stephen H Hughes, Eddy Arnold, 2005, Journal of medicinal chemistry.

Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives

Erik De Clercq, Jan Desmyter, Dominique Schols, 1990, Nature.

Diarylquinolines target subunit c of mycobacterial ATP synthase.

Dirk Bald, Koen Andries, Ismet Dorange, 2007, Nature chemical biology.

The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

Gavin Churchyard, Alexander Pym, Paul Meyvisch, 2009, The New England journal of medicine.

A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis

Hinrich W. H. Göhlmann, Philip Timmerman, Jean-Marc Neefs, 2005, Science.

Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors

Henri Moereels, Koen Andries, Jianping Ding, 1995, Nature Structural Biology.

Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design

James M. Hogle, Koen Andries, Robert A. Grant, 1994, Current Biology.

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

Eduardo Gotuzzo, Alexander Pym, Paul Meyvisch, 2014, The New England journal of medicine.

4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.

Christophe Meyer, Eddy Arnold, Koen Andries, 2005, Journal of medicinal chemistry.

The challenge of new drug discovery for tuberculosis

Eric Arnoult, Koen Andries, K. Andries, 2011, Nature.

Essentiality of FASII pathway for Staphylococcus aureus

Koen Andries, K. Andries, N. Lounis, 2010, Nature.

Bactericidal Potencies of New Regimens Are Not Predictive of Their Sterilizing Potencies in a Murine Model of Tuberculosis

Koen Andries, K. Andries, N. Lounis, 2010, Antimicrobial Agents and Chemotherapy.

Synthesis and anti-HIV activity of 1,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-one (TBO) derivatives. truncated 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-ones (TIBO) analogues

Erik De Clercq, Koen Andries, Rudi Pauwels, 1999 .

In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).

Stephen H Hughes, Peter Williams, Paul J Lewi, 2005, Journal of medicinal chemistry.